ANGLE PLC (LON:AGL) continues to make “good progress” with the enrolment for the clinical study of its Parsortix cancer detection technology.
So far, over 75% of the required 400 patients – 200 with cancer and 200 healthy – have been enrolled in the study.
ANGLE is looking to become the first company to receive Food and Drug Administration clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.
Given the progress to-date, the AIM company now expects the study to be completed during the first quarter of 2019.
Away from the trial, ANGLE has been carrying out more work of its own on Parsortix, which has yielded “new insights” into the system.
“Our significant and sustained efforts to complete the clinical and analytical studies needed to support our FDA submission are progressing well,” said chief executive Andrew Newland.
“We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.”
He added: “This would be a key step in establishing the Parsortix system as the system of choice for CTC liquid biopsy, securing a leading position in the emerging multi-billion-dollar liquid biopsy market.”
Shares fell 4.4% to 41.1p.